Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: Activation of PPAR-α

Toxicology and Applied Pharmacology

Volumn 210, Issue 3, 2006, Pages 225-235

  Hsun Wei Huang, Tom ^a   Peng, Gang ^a   Qian Li, George ^a   Yamahara, Johji ^b   Roufogalis, Basil D ^a   Li, Yuhao ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Pharmafood Institute   (Japan)

Author keywords

Diabetes; Lipid metabolism; Liver; Obesity; Peroxisome proliferator activated receptor ; Salacia oblonga; Steatosis

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ACYL COENZYME A OXIDASE; CARNITINE PALMITOYLTRANSFERASE; CHOLESTEROL; FATTY ACID; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; LUCIFERASE; MANGIFERIN; MESSENGER RNA; OLIVE OIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLANT EXTRACT; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CELL; MACROPHAGE; MOLECULAR MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PLANT ROOT; POSTPRANDIAL STATE; PROTEIN EXPRESSION; RAT; STEATOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; CELL LINE; CHOLESTEROL; FATTY LIVER; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEIN LIPASE; LUCIFERASES; MALE; MEDICINE, AYURVEDIC; OBESITY; PLANT EXTRACTS; PLANT ROOTS; POSTPRANDIAL PERIOD; PPAR ALPHA; RATS; RATS, ZUCKER; SALACIA; TRIGLYCERIDES;

ANIMALIA; SALACIA OBLONGA;

EID: 30844432203     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2005.05.003     Document Type: Article

References (51)

1. E. Aasum, D.D. Belke, D.L. Severson, R.A. Riemersma, M. Cooper, M. Andreassen, and T.S. Larsen Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator Am. J. Physiol.: Heart Circ. Physiol. 283 2002 H949 H957
2. A. Abe, Y. Kiriyama, M. Hirano, T. Miura, H. Kamiya, H. Harashima, and Y. Tokumitsu Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma Eur. J. Pharmacol. 436 2002 7 13
3. R. Alemzadeh, and K.M. Tushaus Modulation of adipoinsular axis in prediabetic ZDF rats by diazoxide Endocrinology 145 2004 5476 5484
4. C. Ameen, U. Edvardsson, A. Ljungberg, L. Asp, P. Akerblad, A. Tuneld, S.O. Olofsson, D. Linden, and J. Oscarsson Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver J. Biol. Chem. 280 2005 1224 1229
5. S. Bonilla, A. Redonnet, C. Noel-Suberville, R. Groubet, V. Pallet, and P. Higueret Effect of a pharmacological activation of PPAR on the expression of RAR and TR in rat liver J. Physiol. Biochem. 57 2001 1 8
6. M.M. Bradford A rapid and sensitive method for the quantition of microgram quantities of protein utilizing the principle of dye-binding Anal. Biochem. 72 1976 248 254
7. K.S. Bramlett, K.A. Houck, K.M. Borchert, M.S. Dowless, P. Kulanthaivel, Y. Zhang, T.P. Beyer, R. Schmidt, J.S. Thomas, L.F. Michael, R. Barr, C. Montrose, P.I. Eacho, G. Cao, and T.P. Burris A natural product ligand of the oxysterol receptor, liver X receptor J. Pharmacol. Exp. Ther. 307 2003 291 296
8. O. Braissant, and W. Wahli Differential expression of peroxisome proliferator-activated receptor-α, -β, and -γ during rat embryonic development Endocrinology (Baltimore) 139 1998 2748 2754
9. H.B. Brewer Jr. Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease Am. J. Cardiol. 83 1999 3F 12F
10. A. Ceriello The postprandial state and cardiovascular disease: relevance to diabetes mellitus Diabetes/Metab. Res. Rev. 16 2000 125 132
11. E. Chaput, R. Saladin, M. Silvestre, and A.D. Edgar Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight Biochem. Biophys. Res. Commun. 271 2000 445 450
12. S. Chitturi, and G.C. Farrell Etiopathogenesis of nonalcoholic steatohepatitis Semin. Liver Dis. 21 2001 27 41
13. J.S. Cohn Postprandial lipemia: emerging evidence for atherogenicity of remnant lipoproteins Can. J. Cardiol. 14 Suppl. B 1998 18B 27B
14. J.P.C. Chandrasena The Chemistry and Pharmacology of Ceylon and Indian Medicinal Plants 1935 H and C Press Colombo, Sri Lanka
15. W.S. Cook, A.V. Yeldandi, M.S. Rao, T. Hashimoto, and J.K. Reddy Less extrahepatic induction of fatty acid beta-oxidation enzymes by PPAR alpha Biochem. Biophys. Res. Commun. 278 2000 250 257
16. G.F. Davies, P.J. McFie, R.L. Khandelwal, and W.J. Roesler Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes J. Pharmacol. Exp. Ther. 300 2002 72 77
17. D. Festi, A. Colecchia, T. Sacco, M. Bondi, E. Roda, and G. Marchesini Hepatic steatosis in obese patients: clinical aspects and prognostic significance Obes. Rev. 5 2004 27 42
18. M. Fischer, M. You, M. Matsumoto, and D.W. Crabb Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice J. Biol. Chem. 278 2003 27997 28004
19. K.J. Foster, A.H. Griffith, K. Dewbury, C.P. Price, and R. Wright Liver disease in patients with diabetes mellitus Postgrad. Med. J. 56 1980 767 772
20. G.A. Francis, J.S. Annicotte, and J. Auwerx PPAR-alpha effects on the heart and other vascular tissues Am. J. Physiol.: Heart Circ. Physiol. 285 2003 H1 H9
21. K.S. Frederiksen, E.M. Wulff, P. Sauerberg, J.P. Mogensen, L. Jeppesen, and J. Fleckner Prediction of PPAR-alpha ligand-mediated physiological changes using gene expression profiles J. Lipid Res. 45 2004 592 601
22. A.M. Gotto Jr. Triglyceride as a risk factor for coronary artery disease Am. J. Cardiol. 82 1998 22Q 25Q
23. M.R. Greenwood The relationship of enzyme activity to feeding behavior in rats: lipoprotein lipase as the metabolic gatekeeper Int. J. Obes. 9 Suppl. 1 1985 67 70
24. T.H. Huang, G. Peng, B.P. Kota, G.Q. Li, J. Yamahara, B.D. Roufogalis, and Y. Li Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model: role of lowering circulating lipids Br. J. Pharmacol. 2005 May 9 (electronic publication ahead of print)
25. M.W. Huff Dietary cholesterol, cholesterol absorption, postprandial lipemia and atherosclerosis Can. J. Clin. Pharmacol. 10 Suppl. A 2003 26A 32A
26. T.S. Ismail, S. Gopalakrishnan, V.H. Begum, and V. Elango Anti-inflammatory activity of Salacia oblonga Wall and Azima tetracantha Lam J. Ethnopharmacol. 56 1997 145 152
27. O. James, and C. Day Non-alcoholic steatohepatitis. Another disease of affluence Lancet 353 1999 1634 1636
28. J.P. Kehrer, S.S. Biswal, E. La, P. Thuillier, K. Datta, S.M. Fischer, and J.P. Vanden Heuvel Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886 Biochem. J. 356 2001 899 906
29. S. Kersten, B. Desvergne, and W. Wahli Roles of PPARs in health and disease Nature 405 2000 421 424
30. K. Koyama, G. Chen, Y. Lee, and R.H. Unger Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity Am. J. Physiol. 273 1997 E708 E713
31. P.J. Larsen, P.B. Jensen, R.V. Sorensen, L.K. Larsen, N. Vrang, E.M. Wulff, and K. Wassermann Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis Diabetes 52 2003 224922 224959
32. G.Y. Lee, N.H. Kim, Z.S. Zhao, B.S. Cha, and Y.S. Kim Peroxisomal-proliferator-activated receptor alpha activates transcription of the rat hepatic malonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level Biochem. J. 378 2004 983 990
33. L. Li, M.C. Beauchamp, and G. Renier Peroxisome proliferator-activated receptor alpha and gamma agonists upregulate human macrophage lipoprotein lipase expression Atherosclerosis 165 2002 101 110
34. Y. Li, G. Peng, Q. Li, S. Wen, T.H. Huang, B.D. Roufogalis, and J. Yamahara Salacia oblonga improves cardiac fibrosis and inhibits postprandial hyperglycemia in obese Zucker rats Life Sci. 75 2004 1735 1746
35. G.D. Lopaschuk Metabolic abnormalities in the diabetic heart Heart Fail. Rev. 7 2002 149 159
36. A. Minnich, N. Tian, L. Byan, and G. Bilder A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle Am. J. Physiol. Endocrinol. Metab. 280 2001 E270 E279
37. T. Miura, N. Iwamoto, M. Kato, H. Ichiki, M. Kubo, Y. Komatsu, T. Ishida, M. Okada, and K. Tanigawa The suppressive effect of mangiferin with exercise on blood lipids in type 2 diabetes Biol. Pharm. Bull. 24 2001 1091 1092
38. D.M. Muoio, J.M. Way, C.J. Tanner, D.A. Winegar, S.A. Kliewer, J.A. Houmard, W.E. Kraus, and G.L. Dohm Peroxisome proliferator-activated receptor-alpha regulates fatty acid utilization in primary human skeletal muscle cells Diabetes 51 2002 901 909
39. N.D. Oakes, P.G. Thalen, S.M. Jacinto, and B. Ljung Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability Diabetes 50 2001 1158 1165
40. A. Sarkar, Y. Sreenivasan, G.T. Ramesh, and S.K. Manna beta-d-Glucoside suppresses tumor necrosis factor-induced activation of nuclear transcription factor kappaB but potentiates apoptosis J. Biol. Chem. 279 2004 33768 33781
41. J.F. Silverman, W.J. Pories, and J.F. Caro Liver pathology in diabetes mellitus and morbid obesity: clinical, pathological, and biochemical considerations Pathol. Annu. 24 1989 275 302
42. A.D. Sniderman Postprandial hypertriglyceridemia(s): time to enlarge our pathophysiologic perspective Eur. J. Clin. Invest. 30 2000 935 937
43. B.G. Stone, and D.H. Van Thiel Diabetes mellitus and the liver Semin. Liver Dis. 5 1985 8 28
44. C. Tikellis, P.J. Wookey, R. Candido, S. Andrikopoulos, M.C. Thomas, and M.E. Cooper Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat Diabetes 53 2004 989 997
45. I.P. Torra, G. Chinetti, C. Duval, J.C. Fruchart, and B. Staels Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice Curr. Opin. Lipidol. 12 2001 245 254
46. J.M. Ye, M.A. Iglesias, D.G. Watson, B. Ellis, L. Wood, P.B. Jensen, R.V. Sorensen, P.J. Larsen, G.J. Cooney, K. Wassermann, and E.W. Kraegen PPARalpha/gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly Am. J. Physiol: Endocrinol. Metab. 284 2003 E531 E540
47. M. Yoshikawa, N. Nishida, H. Shimoda, M. Takada, Y. Kawahara, and H. Matsuda Polyphenol constituents from Salacia species: quantitative analysis of mangiferin with alpha-glucosidase and aldose reductase inhibitory activities Yakushigaku Zasshi 121 2001 371 378
48. M. Yoshikawa, H. Shimoda, N. Nishida, M. Takada, and H. Matsuda Salacia reticulata and its polyphenolic constituents with lipase inhibitory and lipolytic activities have mild antiobesity effects in rats J. Nutr. 132 2002 1819 1824
49. M. Yoshikawa, K. Ninomiya, H. Shimoda, N. Nishida, and H. Matsuda Hepatoprotective and antioxidative properties of Salacia reticulata: preventive effects of phenolic constituents on CCl4-induced liver injury in mice Biol. Pharm. Bull. 25 2002 72 76
50. D.B. Zilversmit Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins Clin. Chem. 41 1995 153 158
51. Y.T. Zhou, M. Shimabukuro, M.Y. Wang, Y. Lee, M. Higa, J.L. Milburn, C.B. Newgard, and R.H. Unger Role of peroxisome proliferator-activated receptor alpha in disease of pancreatic beta cells Proc. Natl. Acad. Sci. U.S.A. 95 1998 8898 8903